UK markets open in 1 hour 12 minutes
  • NIKKEI 225

    27,413.28
    -734.23 (-2.61%)
     
  • HANG SENG

    27,879.02
    -352.02 (-1.25%)
     
  • CRUDE OIL

    65.33
    -0.75 (-1.13%)
     
  • GOLD FUTURES

    1,817.20
    -5.60 (-0.31%)
     
  • DOW

    33,587.66
    -681.50 (-1.99%)
     
  • BTC-GBP

    36,285.66
    -4,674.56 (-11.41%)
     
  • CMC Crypto 200

    1,399.73
    -164.10 (-10.49%)
     
  • ^IXIC

    13,031.68
    -357.75 (-2.67%)
     
  • ^FTAS

    3,986.82
    +23.84 (+0.60%)
     

Highlight to present Phase 2 data at AACR

Highlight Therapeutics
·1-min read

Highlight Therapeutics to present data from Phase 2 immunotherapy studies of liver metastases and melanoma data at AACR Virtual Annual Meeting 2021

MADRID, Spain, April 14, 2021 (GLOBE NEWSWIRE) -- Highlight Therapeutics, (“Highlight”), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, today announced that data from Phase 2 studies of its RNA-based immunotherapy BO-112 will be presented as posters at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2021, April 10-15 and May 17-21.

The e-poster presentations, which are available for browsing on from April 10, 2021, through June 21, 2021, are entitled:

  • Phase IIa open-label clinical study of intratumoral administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer (Abstract number 5289)

  • Phase 2 clinical study to evaluate the efficacy and safety of intratumoral BO-112 in combination with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy (Abstract number 4936)

  • BO-112 as a modifier of the tumor microenvironment for liver metastases (Abstract number 994)

  • A phase I study of intratumoral BO-112 and nivolumab for resectable soft tissue sarcoma (Abstract number 5273)

Click on, or paste the following link into your web browser, to view the associated PDF document.

http://www.rns-pdf.londonstockexchange.com/rns/3658V_1-2021-4-13.pdf

Contacts:
RNS
Customer Services
0044-207797-4400
rns@londonstockexchange.com
http://www.rns.com